ClinicalTrials.gg
CompletedNCT03219957Updated Feb 18, 2020

Study of AT-527 in Healthy and HCV-Infected Subjects

A Phase 1 interventional study of AT-527 and Placebo Comparator in Chronic Hepatitis C, Hepatitis C and Hepatitis C, Chronic, sponsored by Atea Pharmaceuticals, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Hepatitis C, Chronic with a site in Belgium — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Belgium.

Enrollment
32nd of 38
88 · median 266
Started
2017
with 2 others
Phase 1
Only one
of the 46
Registered
42nd of 46
by date
Lead sponsor
3 of 46
Atea Pharmaceuticals, Inc.

Among the 46 studies in Hepatitis C, Chronic with a site in Belgium, this one is the 32nd largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 1, and was the 42nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 46 studies in Hepatitis C, Chronic with a site in Belgium is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies in Hepatitis C, Chronic with a site in Belgium as a file.
02

Study summary

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

03

Conditions studied

  • Chronic Hepatitis C
  • Hepatitis C
  • Hepatitis C, Chronic

Keywords

  • HCV
  • Hepatitis C Virus
  • RNA Viruses
  • Flavivirus
  • Liver Diseases
  • Hepatitis, Viral, Human
  • Flaviviridae Infections
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects (healthy and -infected subjects):

  • Must agree to use two methods of from Screening through 90 days after administration of the last dose of study drug
  • Must have a negative pregnancy test at Screening and prior to dosing
  • Minimum body weight of 50 kg
  • Willing to comply with the study requirements and to provide written

Additional inclusion criteria for HCV-infected subjects:

  • Must have not received prior treatment for HCV infection
  • Documented clinical history compatible with chronic HCV infection
  • Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening.

Exclusion criteria

Exclusion Criteria:

All subjects (healthy and -infected subjects):

  • Pregnant or breastfeeding
  • Infected with virus or
  • Abuse of alcohol or drugs
  • Use of other drugs within 28 days of dosing
  • Other medical conditions or laboratory abnormalities
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    AT-527

    Drug: AT-527

  • Placebo comparator
    Placebo

    Other: Placebo Comparator

Interventions

  • DrugAT-527

    Ascending doses of AT-527 administered orally.

  • OtherPlacebo Comparator

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Number of subjects experiencing treatment-emergent adverse events

    Time frame: Through Day 6 for subjects receiving a single dose

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Number of subjects experiencing treatment-emergent adverse events

    Time frame: Through Day 35 for subjects receiving multiple doses.

Secondary outcomes

  1. Pharmacokinetics (PK) of AT-527

    Maximum plasma concentration (Cmax)

    Time frame: Day 1 for subjects receiving a single dose; Days 1 and 7 for subjects receiving multiple doses

  2. Pharmacokinetics (PK) of AT-527

    Area under the concentration-time curve (AUC)

    Time frame: Day 1 for subjects receiving a single dose; Days 1 and 7 for subjects receiving multiple doses

  3. Antiviral Activity of AT-527

    Change from baseline in plasma HCV RNA

    Time frame: Through Day 6 for subjects receiving a single dose; Through Day 35 for subjects receiving multiple doses.

07

Study locations

2 sites
  • Clinical Trial Site
    Antwerp, Belgium
  • Clinical Trial Site
    Chisinau, Moldova, Republic of
08

References and documents

Publications

  • Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, Pietropaolo K, Murphy RL, Zhou XJ, Sommadossi JP. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 9;63(12):e01201-19. doi: 10.1128/AAC.01201-19. Epub 2019 Sep 30. PubMed 31570394 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jun 2018, 11 months.

Of 21 phase 1 interventional studies under Hepatitis C, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 11 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2017
First posted
Jul 18, 2017
StartActual
Jul 6, 2017
Primary completionActual
Jun 20, 2018
CompletionActual
Jun 20, 2018
Last update
Feb 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03219957
Responsible party
Sponsor
First posted
Jul 18, 2017
Start date
Jul 6, 2017
Primary completion
Jun 20, 2018
Completion
Jun 20, 2018
Last update
Feb 18, 2020

Study contacts

Xiao-Jian Zhou, PhD
study director · Atea Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion